SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VISX -- Ignore unavailable to you. Want to Upgrade?

To: MGV who wrote (1059)4/14/1999 5:45:00 PM
From: kevin mcguire  Read Replies (1) | Respond to of 1754
 
Goldman is the low on the Street @ $2.09...they are $.03 and $.02 below consensus in Q2/Q3 respectively, and $.06 below FY'99 consensus.

IMO, you could see them raise estimates toward $2.20, and the rest of the street move towards the Robbie Stephens & Dillon Read high of $2.25. Perhaps even an upgarde to Buy or Recommended List down the road.

This could be another catalyst for price appreciation...as if today's announcements aren't enough.

Kmags



To: MGV who wrote (1059)4/14/1999 5:52:00 PM
From: Charlie Smith  Read Replies (2) | Respond to of 1754
 
Mark:

Logan emphasized at least three times on the call that the 388 and 699 patents remain valid and enforceable throughout the examination and appeal periods, which could last until 2006.

Charlie



HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News